- Investigator
- Daniel E Soffer
- Status
- Accepting Candidates
- Ages
- 18 Years - 99 Years
- Sexes
- All
Treats Adults
Daniel E Soffer, MD
Cardiologist, Interventional Cardiologist
Daniel E Soffer, MD
(904) 383-1011
Request appointment online
Research at a glance
Research activity
Active clinical trials
My publications
Filter publications
37 publications
2024
Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD.
JACC. Basic to translational science
鈥�2024
P2Y12 Inhibition in Patients Requiring Oral聽Anticoagulation After Percutaneous聽Coronary Intervention: The SWAP-AC-2 Study.
JACC. Cardiovascular interventions
鈥�2024
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.
Thrombosis and haemostasis
鈥�2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.
JACC. Cardiovascular interventions
鈥�2023
Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
鈥�